CriticalAntidepressants. Other antidepressants of herbal origin×Selective 5-HT1B/1D serotonin receptor agonist
Updated · Methodology
Mechanism
St John's wort extract inhibits the synaptosomal reuptake of serotonin, noradrenaline and dopamine (St John's wort summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.1). Sumatriptan is a selective serotonin 5-HT1 receptor agonist (sumatriptan SmPC, AEMPS, section 5.1). The interaction table of the St John's wort SmPC lists increased serotonergic effects and a higher incidence of adverse reactions with triptans, including sumatriptan (St John's wort SmPC, AEMPS, section 4.5). The sumatriptan SmPC also states that adverse reactions may be more common when triptans are used with St John's wort preparations (sumatriptan SmPC, AEMPS, section 4.4). Sumatriptan is cleared mainly by oxidative metabolism via monoamine oxidase A (sumatriptan SmPC, AEMPS, section 5.2). The documents do not describe a pharmacokinetic interaction with St John's wort.
Symptoms
The St John's wort summary of product characteristics (SmPC) warns of increased serotonergic effects and more frequent adverse reactions when St John's wort is combined with triptans (St John's wort SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). According to the European Medicines Agency (EMA) herbal monograph, serotonin syndrome can occur very rarely in combination with serotonin reuptake inhibitors or other serotonergic substances (St John's wort herbal monograph, EMA, section 4.5). Serotonin syndrome may occur with sumatriptan, particularly with selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs), tricyclic antidepressants and monoamine oxidase (MAO) inhibitors (sumatriptan label, US Food and Drug Administration, FDA, section 5.7). St John's wort is not on this list. According to this label, signs include agitation, hallucinations, coma, tachycardia, labile blood pressure, hyperthermia, hyperreflexia, incoordination, nausea, vomiting and diarrhoea. They usually appear within minutes to hours of a new or higher dose of a serotonergic medicine (FDA sumatriptan label, section 5.7).
Management
The Spanish St John's wort summary of product characteristics (SmPC) contraindicates the combination: St John's wort must not be used with medicines of the triptan group, and its interaction table names sumatriptan (St John's wort SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.3 and 4.5). The authorisation of this product has been suspended since 11 June 2026, and there is no other current Spanish St John's wort SmPC. The sumatriptan documents are less strict. The Spanish sumatriptan SmPC states that adverse reactions may be more common with St John's wort preparations but does not prohibit the combination (sumatriptan SmPC, AEMPS, section 4.4). The sumatriptan label of the US Food and Drug Administration (FDA) does not mention St John's wort. If the two have nevertheless been taken together and serotonin syndrome is suspected, stop sumatriptan (FDA sumatriptan label, section 5.7). No document says how long to wait between stopping St John's wort and taking sumatriptan.
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Sumatriptán, Imigran Neo 50 mg (nº registro 66406), sección 4.3 (2025)– AEMPS, CIMA, nº registro 66406 (Imigran Neo 50 mg comprimidos recubiertos con película, GlaxoSmithKline), revisión 10/2025 (la sección 10 indica 08/2025), secciones 4.3, 4.4, 4.5, 4.8 y 5.2
- FDA: IMITREX tablets (sumatriptan) prescribing information (2025)– FDA, DailyMed setid 584abe73-8290-4484-ff8e-5890831c095e (GlaxoSmithKline), revisión 12/2025 (versión 24), secciones 4, 5.7, 5.8, 7.2 y 12.3
- AEMPS: Ficha técnica: Hipérico (Hypericum perforatum) (nº registro 79963), secciones 4.3 y 4.5 (2025)– AEMPS, CIMA, Hipérico Arkopharma cápsulas duras, nº registro 79963, documento 11/2025 (fecha de revisión del texto 09/2016), secciones 4.3, 4.4 y 4.5; autorización suspendida desde el 11.06.2026, única ficha técnica de hipérico no revocada en CIMA
- EMA: European Union herbal monograph on Hypericum perforatum L., herba – Revision 1 (EMA/HMPC/7695/2021) (2022)– EMA, Committee on Herbal Medicinal Products (HMPC), European Union herbal monograph on Hypericum perforatum L., herba, Final – Revision 1, EMA/HMPC/7695/2021, 23.11.2022 (publicada 22.02.2023), secciones 4.1, 4.3 y 4.5